• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by LifeMD Inc.

    7/5/24 4:45:45 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care
    Get the next $LFMD alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on July 5, 2024

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    LIFEMD, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   76-0238453

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

         
    236 Fifth Avenue, Suite 400   10001
    New York, New York   (Zip Code)
    (Address of Principal Executive Offices)    

     

    LIFEMD, INC. THIRD AMENDED AND RESTATED 2020 EQUITY AND INCENTIVE PLAN

    (Full title of the plan)

     

    Justin Schreiber

    236 Fifth Avenue, Suite 400

    New York, NY 10001

    (866) 351-5907

    (Name and address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

    Cam C. Hoang, Esq.

    Dorsey & Whitney LLP

    50 South Sixth Street, Suite 1500

    Minneapolis, Minnesota 55402

    (612) 492-6109

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☒
    Non-accelerated filer ☐ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of this Registration Statement is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to plan participants as required by Rule 428(b)(1).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents previously filed by the Company with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

     

    (1) our Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 11, 2024;
       
    (3) our Definitive Proxy Statement, filed on April 29, 2024, as amended on May 24, 2024;
       
    (4) our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 8, 2024;
       
    (2) our Current Reports on Form 8-K, filed on May 2, 2024 and June 18, 2024; and
       
    (5) the description of our Common Stock contained in the our Registration Statement on Form 8-A (File No. 001-39785) filed on December 9, 2020, including any amendment or report filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to the Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents, except that information furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and any exhibit relating to such information, shall not be deemed to be incorporated by reference in this Registration Statement.

     

    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

     

     

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Our bylaws provide for indemnification by us of our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law (the “DGCL”). Section 145 of the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the corporation. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise.

     

    We have entered into indemnification agreements with each of our directors and executive officers to provide contractual indemnification in addition to the indemnification provided in our bylaws. Each indemnification agreement provides for indemnification and advancements of certain expenses and costs relating to claims, suits or proceedings arising from their service, to the maximum extent permitted by applicable law.

     

    Our amended certificate of incorporation provides that, to the maximum extent permitted by the DGCL, no director shall be personally liable to us or our shareholders for monetary damages for breach of fiduciary duty as director. Section 102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its shareholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, or (iv) for any transaction from which the director derived an improper personal benefit.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit No.   Description of Exhibit
         
    4.1   Certificate of Incorporation, As Amended (incorporated by reference to Exhibit 3.1 to the Form 10-K filed with the SEC on March 11, 2024)
    4.2   Bylaws of Immudyne, Inc. effective April 9, 2018 (incorporated by reference to Exhibit 3.2 to the Form 10-K filed with the SEC on March 11, 2024)
    4.3   LifeMD, Inc. Third Amended and Restated 2020 Equity and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on June 18, 2024)
    4.4   Form of Non-Qualified Option Agreement (Non-Employee Director Awards) (incorporated by reference to Exhibit 4.5 to the Form 10-K filed with the SEC on March 11, 2024)
    4.5   Form of Non-Qualified Option Agreement (Employee Awards) (incorporated by reference to Exhibit 4.6 to the Form 10-K filed with the SEC on March 11, 2024)
    4.6   Form of Restricted Stock Award Agreement (incorporated by reference to Exhibit 4.7 to the Form 10-K filed with the SEC on March 11, 2024)
    5.1*   Opinion of Dorsey & Whitney LLP
    23.1*   Consent of Marcum LLP, independent registered public accounting firm of LifeMD, Inc.
    23.2*   Consent of Dorsey & Whitney LLP (included as part of Exhibit 5.1 hereto)
    24.1*   Power of Attorney (included on signature page)
    107*   Filing Fee Table

     

      * Filed herewith.

     

     

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on July 5, 2024.

     

      LIFEMD, INC.
         
      By /s/ Justin Schreiber
        Justin Schreiber
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Justin Schreiber, Marc Benathen and Eric Yecies as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign, execute and file all amendments (including, without limitation, post- effective amendments) to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name and Signature   Title   Date
             
    /s/ Justin Schreiber   Chief Executive Officer and Director   July 5, 2024
    Justin Schreiber   (Principal Executive Officer)    
             
    /s/ Marc Benathen   Chief Financial Officer   July 5, 2024
    Marc Benathen   (Principal Financial Officer)    
             
    /s/ Maria Stan   Chief Accounting Officer and Controller   July 5, 2024
    Maria Stan   (Principal Accounting Officer)    
             
    /s/ Naveen Bhatia   Director   July 5, 2024
    Naveen Bhatia        
             
      Director  
    John R. Strawn, Jr.        
             
    /s/ Roberto Simon   Director   July 5, 2024
    Roberto Simon        
             
      Director  
    Joseph DiTrolio        
             
    /s/ Robert Jindal   Director   July 5, 2024
    Robert Jindal        
             
      Director  
    Joan LaRovere        
             
    /s/ William J. Febbo   Director   July 5, 2024
    William J. Febbo        
             
    /s/ Calum MacRae   Director   July 5, 2024
    Calum MacRae        

     

     

    Get the next $LFMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFMD

    DatePrice TargetRatingAnalyst
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    12/10/2024$12.00Buy
    Lake Street
    12/4/2024$7.00Neutral
    Mizuho
    8/23/2024$11.00Buy
    B. Riley Securities
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    11/30/2023$10.00Buy
    Craig Hallum
    7/21/2023$7.00Overweight
    Cantor Fitzgerald
    7/3/2023$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $LFMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Marketing Officer Friedeman Jessica sold $54,158 worth of shares (15,000 units at $3.61), decreasing direct ownership by 7% to 205,000 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    12/11/25 5:11:13 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Director Strawn John R Jr was granted 22,365 shares, increasing direct ownership by 6% to 413,001 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/8/25 6:25:50 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Director Larovere Joan was granted 22,365 shares, increasing direct ownership by 26% to 107,050 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/8/25 6:03:32 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

    NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility ("RCF") with Citizens Bank, N.A. ("Citizens"). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was drawn on the RCF as the Company believes its cash on hand and expected cash flow are sufficient to fund its organic growth initiatives. "We are very pleased to close this revolving cred

    1/6/26 8:30:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

    NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk's Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehealth platform. Eligible patients can access the Wegovy® pill for as little as $149 per month, further expanding LifeMD's portfolio of branded obesity treatments. This announcement broadens LifeMD's long-standing collaboration with Novo Nordisk. As part of the relationship, LifeMD is featured on the NovoCare® and Wegovy® websites as a truste

    1/5/26 8:05:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, spanning primary ca

    12/26/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    SEC Filings

    View All

    LifeMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LifeMD, Inc. (0000948320) (Filer)

    1/6/26 9:19:16 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by LifeMD Inc.

    10-Q - LifeMD, Inc. (0000948320) (Filer)

    11/17/25 4:52:52 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LifeMD, Inc. (0000948320) (Filer)

    11/17/25 4:10:58 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on LifeMD with a new price target

    BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

    6/18/25 10:55:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Lake Street initiated coverage on LifeMD with a new price target

    Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

    12/10/24 8:29:49 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Mizuho initiated coverage on LifeMD with a new price target

    Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00

    12/4/24 7:42:36 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    9/12/24 2:10:03 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Leadership Updates

    Live Leadership Updates

    View All

    LifeMD Names COO and Promotes Two Executives

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD's growth, most recently serving as Senior Vice President of Operations. "Shayna's proven track record of building and managing an industry-leading operations team and infrastructure in a complex and rapidly growing environment makes her the ideal leader to step into the role of COO," said Justin Schreiber, Chairman and Chief Executive Officer of L

    7/31/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Set to Join the Russell 3000 Index

    NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind

    5/29/24 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Appoints Dr. Calum MacRae to its Board of Directors

    NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno

    4/29/24 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Financials

    Live finance-specific insights

    View All

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, spanning primary ca

    12/26/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025. The change to LifeMD's third quarter 2025 earnings release date relates to corrections the Company identified related to the recognition of revenue with offsetting related balance sheet accounts for the twelve months ended December 31, 202

    11/5/25 5:15:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD to Report Third Quarter 2025 Financial Results on November 6

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on November 6, 2025, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-245-3047International Dial-In:203-518-9765Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and ph

    10/23/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    11/14/24 10:42:44 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by LifeMD Inc. (Amendment)

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    2/14/24 3:33:22 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by LifeMD Inc.

    SC 13G - LifeMD, Inc. (0000948320) (Subject)

    10/6/23 5:26:16 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care